Cargando…

Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan

Testing for SARS-CoV-2 antibodies is commonly used to determine prior COVID-19 infections and to gauge levels of infection- or vaccine-induced immunity. Michigan Medicine, a primary regional health center, provided an ideal setting to understand serologic testing patterns over time. Between 27 April...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhangchen, Salerno, Stephen, Shi, Xu, Lee, Seunggeun, Mukherjee, Bhramar, Fritsche, Lars G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509702/
https://www.ncbi.nlm.nih.gov/pubmed/34640359
http://dx.doi.org/10.3390/jcm10194341
_version_ 1784582406563430400
author Zhao, Zhangchen
Salerno, Stephen
Shi, Xu
Lee, Seunggeun
Mukherjee, Bhramar
Fritsche, Lars G.
author_facet Zhao, Zhangchen
Salerno, Stephen
Shi, Xu
Lee, Seunggeun
Mukherjee, Bhramar
Fritsche, Lars G.
author_sort Zhao, Zhangchen
collection PubMed
description Testing for SARS-CoV-2 antibodies is commonly used to determine prior COVID-19 infections and to gauge levels of infection- or vaccine-induced immunity. Michigan Medicine, a primary regional health center, provided an ideal setting to understand serologic testing patterns over time. Between 27 April 2020 and 3 May 2021, characteristics for 10,416 individuals presenting for SARS-CoV-2 antibody tests (10,932 tests in total) were collected. Relative to the COVID-19 vaccine roll-out date, 14 December 2020, the data were split into a pre- (8026 individuals) and post-vaccine launch (2587 individuals) period and contrasted with untested individuals to identify factors associated with tested individuals and seropositivity. Exploratory analysis of vaccine-mediated seropositivity was performed in 347 fully vaccinated individuals. Predictors of tested individuals included age, sex, smoking, neighborhood variables, and pre-existing conditions. Seropositivity in the pre-vaccine launch period was 9.2% and increased to 46.7% in the post-vaccine launch period. In the pre-vaccine launch period, seropositivity was significantly associated with age (10 year; OR = 0.80 (0.73, 0.89)), ever-smoker status (0.49 (0.35, 0.67)), respiratory disease (4.38 (3.13, 6.12)), circulatory disease (2.09 (1.48, 2.96)), liver disease (2.06 (1.11, 3.84)), non-Hispanic Black race/ethnicity (2.18 (1.33, 3.58)), and population density (1.10 (1.03, 1.18)). Except for the latter two, these associations remained statistically significant in the post-vaccine launch period. The positivity rate of fully vaccinated individual was 296/347(85.3% (81.0%, 88.8%)).
format Online
Article
Text
id pubmed-8509702
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85097022021-10-13 Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan Zhao, Zhangchen Salerno, Stephen Shi, Xu Lee, Seunggeun Mukherjee, Bhramar Fritsche, Lars G. J Clin Med Article Testing for SARS-CoV-2 antibodies is commonly used to determine prior COVID-19 infections and to gauge levels of infection- or vaccine-induced immunity. Michigan Medicine, a primary regional health center, provided an ideal setting to understand serologic testing patterns over time. Between 27 April 2020 and 3 May 2021, characteristics for 10,416 individuals presenting for SARS-CoV-2 antibody tests (10,932 tests in total) were collected. Relative to the COVID-19 vaccine roll-out date, 14 December 2020, the data were split into a pre- (8026 individuals) and post-vaccine launch (2587 individuals) period and contrasted with untested individuals to identify factors associated with tested individuals and seropositivity. Exploratory analysis of vaccine-mediated seropositivity was performed in 347 fully vaccinated individuals. Predictors of tested individuals included age, sex, smoking, neighborhood variables, and pre-existing conditions. Seropositivity in the pre-vaccine launch period was 9.2% and increased to 46.7% in the post-vaccine launch period. In the pre-vaccine launch period, seropositivity was significantly associated with age (10 year; OR = 0.80 (0.73, 0.89)), ever-smoker status (0.49 (0.35, 0.67)), respiratory disease (4.38 (3.13, 6.12)), circulatory disease (2.09 (1.48, 2.96)), liver disease (2.06 (1.11, 3.84)), non-Hispanic Black race/ethnicity (2.18 (1.33, 3.58)), and population density (1.10 (1.03, 1.18)). Except for the latter two, these associations remained statistically significant in the post-vaccine launch period. The positivity rate of fully vaccinated individual was 296/347(85.3% (81.0%, 88.8%)). MDPI 2021-09-24 /pmc/articles/PMC8509702/ /pubmed/34640359 http://dx.doi.org/10.3390/jcm10194341 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhao, Zhangchen
Salerno, Stephen
Shi, Xu
Lee, Seunggeun
Mukherjee, Bhramar
Fritsche, Lars G.
Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan
title Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan
title_full Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan
title_fullStr Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan
title_full_unstemmed Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan
title_short Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan
title_sort understanding the patterns of serological testing for covid-19 pre- and post-vaccination rollout in michigan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509702/
https://www.ncbi.nlm.nih.gov/pubmed/34640359
http://dx.doi.org/10.3390/jcm10194341
work_keys_str_mv AT zhaozhangchen understandingthepatternsofserologicaltestingforcovid19preandpostvaccinationrolloutinmichigan
AT salernostephen understandingthepatternsofserologicaltestingforcovid19preandpostvaccinationrolloutinmichigan
AT shixu understandingthepatternsofserologicaltestingforcovid19preandpostvaccinationrolloutinmichigan
AT leeseunggeun understandingthepatternsofserologicaltestingforcovid19preandpostvaccinationrolloutinmichigan
AT mukherjeebhramar understandingthepatternsofserologicaltestingforcovid19preandpostvaccinationrolloutinmichigan
AT fritschelarsg understandingthepatternsofserologicaltestingforcovid19preandpostvaccinationrolloutinmichigan